Market closedNon-fractional
DiaMedica Therapeutics Inc. Common Stock/DMAC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About DiaMedica Therapeutics Inc. Common Stock
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
Ticker
DMAC
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Minneapolis, United States
Employees
19
Website
www.diamedica.com
DMAC Metrics
BasicAdvanced
$110M
Market cap
-
P/E ratio
-$0.54
EPS
1.73
Beta
-
Dividend rate
Price and volume
Market cap
$110M
Beta
1.73
Financial strength
Current ratio
18.144
Quick ratio
17.927
Long term debt to equity
0.634
Total debt to equity
0.82
Management effectiveness
Return on assets (TTM)
-33.79%
Return on equity (TTM)
-52.50%
Valuation
Price to book
2.37
Price to tangible book (TTM)
2.37
Price to free cash flow (TTM)
-5.059
Growth
Earnings per share change (TTM)
-6.93%
3-year earnings per share growth
-11.69%
What the Analysts think about DMAC
Analyst Ratings
Majority rating from 3 analysts.
DMAC Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$5.1M
-0.00%
Profit margin
0.00%
NaN%
DMAC Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.16
-$0.12
-$0.14
-$0.14
-
Expected
-$0.18
-$0.13
-$0.14
-$0.16
-$0.16
Surprise
-9.43%
-5.26%
0.00%
-10.64%
-
DMAC News
AllArticlesVideos
DiaMedica Therapeutics Announces $11.8 Million Private Placement
Business Wire·1 week ago
DiaMedica Therapeutics Inc. (DMAC) Q1 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for DiaMedica Therapeutics Inc. Common Stock stock?
DiaMedica Therapeutics Inc. Common Stock (DMAC) has a market cap of $110M as of July 06, 2024.
What is the P/E ratio for DiaMedica Therapeutics Inc. Common Stock stock?
The price to earnings (P/E) ratio for DiaMedica Therapeutics Inc. Common Stock (DMAC) stock is 0 as of July 06, 2024.
Does DiaMedica Therapeutics Inc. Common Stock stock pay dividends?
No, DiaMedica Therapeutics Inc. Common Stock (DMAC) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next DiaMedica Therapeutics Inc. Common Stock dividend payment date?
DiaMedica Therapeutics Inc. Common Stock (DMAC) stock does not pay dividends to its shareholders.
What is the beta indicator for DiaMedica Therapeutics Inc. Common Stock?
DiaMedica Therapeutics Inc. Common Stock (DMAC) has a beta rating of 1.73. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell DiaMedica Therapeutics Inc. Common Stock stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.